NCT03415659: Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors

NCT03415659
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 70 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Subject who has the symptoms of CNS metastases
https://ClinicalTrials.gov/show/NCT03415659

Comments are closed.

Up ↑